Welcome to our dedicated page for Telix Pharmaceuticals SEC filings (Ticker: TLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Telix Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Telix Pharmaceuticals's regulatory disclosures and financial reporting.
Telix Pharmaceuticals Limited reports Q2 2026 group revenue of US$247 million, up 21% year-over-year and 7% quarter-over-quarter. Precision Medicine revenue was US$202 million, up 30% year-over-year and 9% quarter-over-quarter, while Telix Manufacturing Solutions contributed US$45 million.
For FY 2026, Telix expects revenue and other income to exceed US$1 billion, with revenue tracking toward the upper end of its US$950–US$970 million range, plus US$40 million in non-refundable income from a strategic collaboration with Regeneron. R&D spending guidance is increased to US$230–US$270 million to accelerate late-stage programs, including TLX597-Tx and Pixclara label expansion.
The Therapeutics pipeline advanced with FDA alignment to move TLX591-Tx’s ProstACT Global Phase 3 study to Part 2 in the U.S., first patients dosed in pivotal trials for TLX250-Tx (kidney cancer) and TLX101-Tx (glioblastoma), and strong enrollment across multiple studies. In Precision Medicine, Telix rapidly enrolled 338 patients in the BiPASS Phase 3 prostate cancer study, progressed Japanese and U.S. regulatory paths for Illuccix, Pixclara and Zircaix, and expanded manufacturing capacity in Australia, Belgium and Japan. Telix also entered a Regeneron collaboration, received US$40 million upfront, refinanced with US$600 million of 2031 convertible bonds, and appointed three new Non-Executive Directors.
Telix Pharmaceuticals reports alignment with the U.S. FDA to advance Part 2 of its ProstACT Global Phase 3 trial of TLX591-Tx in metastatic castration-resistant prostate cancer. The FDA confirmed that Part 1 safety data are sufficient to enable progression of Part 2 in the U.S. and agreed with the clinical protocol, statistical analysis plan and ongoing safety monitoring.
In Part 2, TLX591-Tx is given in two doses 14 days apart alongside one of three standard-of-care therapies: abiraterone, enzalutamide or docetaxel, under a randomized design. The trial’s safety and dosimetry lead-in (Part 1) enrolled 36 patients and is complete, and the global expansion (Part 2) targets approximately 490 patients. Enrollment continues in multiple countries, while U.S. initiation remains subject to FDA review of an Investigational New Drug amendment. Telix highlights TLX591-Tx as part of a broader radiopharmaceutical pipeline spanning prostate, brain and kidney cancers.
Telix Pharmaceuticals Limited submitted a Form 6-K as a foreign private issuer, forwarding materials from its Annual General Meeting held in May 2026. The filing makes available the Chairman and CEO addresses, an AGM presentation, and the results of the AGM as exhibits for U.S. investors.
Telix Pharmaceuticals Ltd filed an initial Form 3 identifying David N. Gill as a director of the company. The filing’s transaction summary shows no reported purchases, sales, exercises, gifts, or other share movements, and net buy/sell activity is neutral in this excerpt.
Telix Pharmaceuticals Ltd director William R. Jellison has filed an initial Form 3, which is a statement of beneficial ownership for company insiders. This filing lists him as a director but does not report any share transactions or holdings changes, serving mainly as a baseline disclosure.
Telix Pharmaceuticals Ltd filed an initial Form 3 for board member Maria Rivas. This filing establishes her status as a director and provides a baseline disclosure of her beneficial ownership as an insider. The data provided shows no reported purchases, sales, exercises, gifts, or other equity transactions.
Telix Pharmaceuticals Ltd MD & Group CEO Dr. Christian Behrenbruch, through Elk River Holdings Pty Ltd, made two open-market purchases of Ordinary Shares. On April 28 and 29, he indirectly bought a combined 67,935 shares at average prices around $14.48 and $14.87 per share, reported in Australian Dollars. After these transactions, his indirect holdings rose to 20,742,935 Ordinary Shares. The filing notes that the reported prices are volume-weighted averages for multiple trades within specified price ranges.
Telix Pharmaceuticals Limited filed a Form 6-K as a foreign private issuer. The filing forwards to U.S. investors an Australian Securities Exchange announcement titled “Telix Announces Settlement of US$600M Convertible Bonds,” attached as Exhibit 99.1. The report is signed by Group General Counsel Christian Krautkramer.
Telix Pharmaceuticals Limited, a foreign private issuer, submitted a Form 6-K relating to its shareholder meeting materials. On April 21, 2026 in Melbourne, the company lodged with the Australian Securities Exchange an announcement titled “Telix Notice of AGM, Proxy Form and Online Guide,” which is furnished to U.S. investors as Exhibit 99.1.